30 closest matches · ranked by relevance
Epilepsy · Epilepsy, Generalized · Seizures
Primary: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). — 41.2; 49.4; 68.3; 12.1 Percent Reduction — p=0.0120
Epilepsy · Lennox Gastaut Syndrome
Primary: Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period — -41.86; -37.16; -17.17 percentage change — p=0.0047
Lennox Gastaut Syndrome
Primary: Part 1: Percent Change From Baseline in the Frequency of Seizures That Result in Drops (ESC-confirmed) in the Combined Titration and Maintenance Period (T+M) in the…
Epilepsy · Epilepsy, Generalized · Seizures
Primary: Percent Reduction in Number of Drop Seizures. — 10.1; 85.2 Percent Reduction — p=<0.0182
Lennox-Gastaut Syndrome
Primary: Number of Seizure After Treatment by tDCS — 80.67; 93.43; 35.53; 93.14 seizures — p=<0.05
Lennox-Gastaut Syndrome
Primary: Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment — 92.3 percentage of drop seizures
Lennox Gastaut Syndrome (LGS)
Primary: Percent Change From Baseline in Major Motor Drop (MMD) Seizure Frequency Per 28 Days During the Full Treatment Period — -6.69; -6.11 percent change — p==0.785
Lennox-Gastaut Syndrome
Primary: Percent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days) — -24.20; -3.25 Percent Change — p=0.003
Epilepsy · Lennox-Gastaut Syndrome
Primary: Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period — -43.90; -21.80 percentage change — p=0.0135
Lennox-Gastaut Syndrome
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Rufinamide — 54; 38; 9; 2 Participants
Epilepsy · Dravet Syndrome · Lennox-Gastaut Syndrome
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Occurring in ≥5% of Participants in Any Treatment Group — 306; 353; 135; 140 participants
Seizures
Primary: Percentage of Participants With Adverse Events — 88.9; 92.3; 88.2; 90.4 Percentage of participants
Lennox-Gastaut Syndrome
Primary: Child Behavior Checklist (CBCL) Total Problem T-scores at the End of 2-year Treatment Period — 55.7; 54.8 score on a scale — p=0.6928
Epilepsy
Primary: Change in Partial Onset Seizure (POS) Frequency Per 28 Days From Baseline to the Maintenance Period — -1.55; -3.05 Seizures per 28 days — p==0.0003
Dravet Syndrome · Lennox Gastaut Syndrome · Epileptic Encephalopathy
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 75.5 percentage of participants
Epilepsy
Primary: Number of Study Participants With Treatment-emergent Adverse Events (TEAEs) Over the Duration of the Treatment Period — 222 Participants
Epilepsy · Generalized Tonic-Clonic Seizures
Primary: Percentage Change From the Combined Baseline in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 28-week Treatment Period (Dose Adjustment + Evaluation…
Epilepsy With Partial-onset Seizures
Primary: Change in Average Daily Frequency (ADF) of Electrographic Partial-onset Seizures From End-of-Baseline (EOB) Period Video-EEG to End-of-Maintenance (EOM) Period Video-EEG…
Epilepsy · Generalized Tonic-clonic Seizures
Primary: The Percent Change From the Combined Baseline (4-week Retrospective Baseline and 4-week Prospective Baseline) in the Generalized Tonic-clonic Seizure Frequency Per Week…
Status Epilepticus · Convulsive Status EPILEPTICUS · Non Convulsive Status Epilepticus
Primary: Number of Participants Who Did Not Require an IV Anesthetic Drug for SE Treatment — 5; 4; 8 Participants
Epilepsy
Primary: Mean Changes in Count of Generalized Spike-wave Discharges on 24-hour Ambulatory Electroencephalogram (EEG) From Visit 2 to Visit 6 — -4.55; -166.22; -203.12 discharges
Epilepsy
Primary: Number of Participants With Serious Adverse Events (SAE) — 177 Participants
Drug Resistant Partial Onset Seizure
Primary: Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period — -21.28; -10.25 Percent change — p=0.1788
Partial Epilepsies
Primary: The Proportion of Subjects Who Achieved "Seizure-free Status" During the First 12 Weeks of the Maintenance Phase — 37.5; 14.9 percentage of subjects
Generalized Tonic Clonic Seizures
Primary: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase — 1.17; 1.13; 1.14 Seizure…
Tuberous Sclerosis
Primary: Percent Change From Baseline in 28-day Seizure Frequency Through the End of 12-Week Treatment Period — -16.61 Percent change
Epilepsy, Partial Seizures · Epilepsy, Primary Generalized Tonic-Clonic Seizures
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs), Treatment Emergent Serious Adverse Events (SAEs), Treatment Related AEs and Treatment Related SAEs…
Epilepsy
Primary: Time to the Second Primary Generalized Tonic Clonic (PGTC) Seizure During the 24-week Treatment Period From Visit 2 (Week 0) to Visit 10 (Week 24) — 76; 49 events…
Epilepsy
Primary: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) — 7 Participants
Epileptic Encephalopathy · Continuous Spike and Wave During Sleep
Primary: Ratio of Spike-Wave Index (SWI) During First Hour of Nonrapid Eye Movement (NREM) Sleep at Week 6 — -0.02; 0.01 Log-transformed ratio — p=0.4326